DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Breast Cancer Stage IV
Surgery
Radiotherapy

Interventions: Drug: Palbociclib
Other: locoregional treatment

First Posted Date: 2019-03-12

Last Posted Date: 2023-12-07

Lead Sponsor: UNICANCER

Target Recruit Count: 200

Registration Number: NCT03870919

Locations: 🇫🇷
ICM Val d'Aurelle, Montpellier, France
🇫🇷
Hôpital Saint Louis APHP, Paris, France
🇫🇷
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France

and more 22 locations

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Recruiting

Conditions: Lung Cancer

First Posted Date: 2019-02-20

Last Posted Date: 2025-01-17

Lead Sponsor: UNICANCER

Target Recruit Count: 70000

Registration Number: NCT03848052

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇫🇷
Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller, Mulhouse, France

and more 18 locations

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Phase 2

Completed

Conditions: Oropharynx Cancer

Interventions: Drug: Nivolumab
Radiation: Chemoradiation

First Posted Date: 2019-02-12

Last Posted Date: 2025-03-04

Lead Sponsor: UNICANCER

Target Recruit Count: 62

Registration Number: NCT03838263

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
Hopital Tenon, Paris, France
🇫🇷
Hopital Europeen Georges Pompidou, Paris, France

and more 8 locations

Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients

Phase 2

Withdrawn

Conditions: Breakthrough Pain

Interventions: Drug: Fentanyl citrate
Drug: Placebo

First Posted Date: 2019-01-18

Last Posted Date: 2020-04-22

Lead Sponsor: UNICANCER

Registration Number: NCT03809455

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Phase 3

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: BCG
Drug: Atezolizumab

First Posted Date: 2019-01-10

Last Posted Date: 2024-12-11

Lead Sponsor: UNICANCER

Target Recruit Count: 517

Registration Number: NCT03799835

Locations: 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷
Groupe Hospitalier Paris Saint Joseph, Paris, France
🇫🇷
Hôpital privé de la Louvière, Lille, France

and more 35 locations

Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer

Phase 2

Active, not recruiting

Conditions: Unresectable Malignant Neoplasm
Esophagus Cancer

Interventions: Drug: Durvalumab
Combination Product: IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)

First Posted Date: 2018-12-17

Last Posted Date: 2024-09-30

Lead Sponsor: UNICANCER

Target Recruit Count: 112

Registration Number: NCT03777813

Locations: 🇫🇷
Centre Oscar Lambret, CLCC UNICANCER, Lille, France
🇫🇷
Hôpital Saint Louis, APHP, Paris, France
🇫🇷
Hôpital Haut-Lévêque, Pessac, France

and more 4 locations

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Non-Small Cell Carcinoma of Lung, TNM Stage 4

Interventions: Radiation: Radiotherapy
Drug: Pembrolizumab
Drug: Chemotherapy

First Posted Date: 2018-12-13

Last Posted Date: 2023-12-18

Lead Sponsor: UNICANCER

Target Recruit Count: 327

Registration Number: NCT03774732

Locations: 🇫🇷
Hôpital Simone Veil Blois, Blois, France
🇫🇷
Centre Hospitalier Dr Jean-Eric TECHER, Calais, France
🇫🇷
CHRU de Brest, Brest, France

and more 53 locations

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Phase 2

Suspended

Conditions: Oxaliplatin-induced Peripheral Neuropathy

Interventions: Drug: Placebo Oral Tablet
Drug: Riluzole

First Posted Date: 2018-10-29

Last Posted Date: 2025-04-23

Lead Sponsor: UNICANCER

Target Recruit Count: 80

Registration Number: NCT03722680

Locations: 🇫🇷
CHU de Clermont -Ferrand, Clermont-Ferrand, France
🇫🇷
ICO - Site Paul Papin, Angers, France
🇫🇷
CH Beauvais, Beauvais, France

and more 13 locations

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Phase 1

Terminated

Conditions: Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction

Interventions: Combination Product: Regorafenib and Irinotecan
Drug: Irinotecan

First Posted Date: 2018-10-26

Last Posted Date: 2023-10-16

Lead Sponsor: UNICANCER

Target Recruit Count: 89

Registration Number: NCT03722108

Locations: 🇫🇷
Centre de Cancérologie du Grand Montpellier, Montpellier, France
🇫🇷
CHU Dupuytren, Limoges, France
🇫🇷
Clinique de Flandre, Coudekerque-Branche, France

and more 24 locations

Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2018-10-05

Last Posted Date: 2024-12-04

Lead Sponsor: UNICANCER

Target Recruit Count: 79

Registration Number: NCT03697850

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷
Institut Bergonie, Bordeaux, France

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy